Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Lidocaine
Overview
What is Ztlido?
ZTLIDO (lidocaine topical system) 1.8% is a single-layer, drug-in-adhesive topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. The release liner is removed prior to application to the skin. The size of ZTLIDO is 10 cm × 14 cm × 0.08 cm.
Lidocaine, an amide local anesthetic, is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl), has an octanol:water partition ratio of 43 at pH 7.4, and has the following structure:
Each ZTLIDO contains 36 mg of lidocaine (18 mg per gram adhesive) in a non-aqueous base and also contains the following inactive ingredients: butylated hydroxytoluene, dipropylene glycol, isostearic acid, mineral oil, polyisobutylene, silicone dioxide, styrene/isoprene/styrene block copolymer, and terpene resin.
What does Ztlido look like?
What are the available doses of Ztlido?
ZTLIDO 1.8% is available as a single-use topical system (
).
What should I talk to my health care provider before I take Ztlido?
Lactation
8.2
How should I use Ztlido?
ZTLIDO (lidocaine topical system) 1.8% is indicated for relief of pain associated with post-herpetic neuralgia (PHN).
What interacts with Ztlido?
Sorry No Records found
What are the warnings of Ztlido?
Sorry No Records found
What are the precautions of Ztlido?
Sorry No Records found
What are the side effects of Ztlido?
Sorry No records found
What should I look out for while using Ztlido?
ZTLIDO is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
What might happen if I take too much Ztlido?
Lidocaine overdose from cutaneous absorption is rare, but could occur. If there is any suspicion of lidocaine overdose, check drug blood concentration. The management of overdose includes close monitoring, supportive care, and symptomatic treatment. Dialysis is of negligible value in the treatment of acute overdose with lidocaine.
In the absence of massive topical overdose or oral ingestion, evaluation of symptoms of toxicity should include consideration of other etiologies for the clinical effects, or overdosage from other sources of lidocaine or other local anesthetics.
How should I store and handle Ztlido?
ZTLIDO (lidocaine topical system) 1.8% is available as the following:Carton of 30 topical systems, packaged into individual child-resistant envelopes.NDC 69557-111-30Store at 68-77°F (20-25°C). [See USP Controlled Room Temperature].ZTLIDO (lidocaine topical system) 1.8% is available as the following:Carton of 30 topical systems, packaged into individual child-resistant envelopes.NDC 69557-111-30Store at 68-77°F (20-25°C). [See USP Controlled Room Temperature].ZTLIDO (lidocaine topical system) 1.8% is available as the following:Carton of 30 topical systems, packaged into individual child-resistant envelopes.NDC 69557-111-30Store at 68-77°F (20-25°C). [See USP Controlled Room Temperature].ZTLIDO (lidocaine topical system) 1.8% is available as the following:Carton of 30 topical systems, packaged into individual child-resistant envelopes.NDC 69557-111-30Store at 68-77°F (20-25°C). [See USP Controlled Room Temperature].
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Lidocaine is an amide local anesthetic. Lidocaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses.
Non-Clinical Toxicology
ZTLIDO is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.The following serious adverse reactions are described elsewhere in the labeling:
The following adverse reactions from voluntary reports or clinical studies have been reported with lidocaine. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Skin and subcutaneous tissues
Immune system
Central Nervous System
Cardiovascular
Other
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).